Dendreon Corp. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported net loss of $45,551,000 or $0.40 per basic and diluted share on revenue of $25,000 against net loss of $26,777,000 or $0.29 per basic and diluted share on revenue of $26,000 for the same period a year ago. Loss from operations of $25,770,000 compared to $17,259,000 for the same period a year ago. For the nine months, the company reported net loss of $187,652,000 or $1.79 per basic and diluted share on revenue of $80,000 against net loss of $62,807,000 or $0.71 per basic and diluted share on revenue of $83,000 for the same period a year ago. Loss from operations of $63,659,000 compared to $54,968,000 for the same period a year ago.

Dendreon Corp. expected to Report Fiscal Year 2009 Results on March 13, 2010. This event was calculated by Capital IQ (Created on November 9, 2009).

Dendreon Corp. announced that it has completed the submission of the amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T), the Company’s lead investigational product, to the U.S. Food and Drug Administration (FDA). Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC). If approved by the FDA, PROVENGE would represent the first product in the new therapeutic class known as active cellular immunotherapies. The amended BLA includes data from the IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) trial, which was conducted under a Special Protocol Assessment agreement with the FDA. The IMPACT study met its pre-specified primary endpoint demonstrating a statistically significant improvement in overall survival in men with metastatic CRPC. PROVENGE is available through several ongoing clinical trials, including OpenACT, an open label trial enrolling men with metastatic CRPC, ProACT (PROstate cancer Active Cellular immunoTherapy), and NeoACT (NEOadjuvant Active Cellular immunotherapy).